Abbott's xience™ stent receives european approval for one-month dual anti-platelet therapy (dapt) for high bleeding risk patients

Abbott park, ill., april 6, 2021 /prnewswire/ -- abbott (nyse: abt) today announced its xience stent has received ce mark in europe for shorter duration of dual anti-platelet therapy (dapt) – as short as 28 days, the shortest indication available in the world – for patients with high bleeding risk (hbr).
ABT Ratings Summary
ABT Quant Ranking